脑脊液 α- 突触核蛋白有助于阿尔茨海默病的鉴别诊断。
Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of Alzheimer's disease.
机构信息
Department of Pathology, University of Washington School of Medicine, Seattle, WA, USA.
Department of Pathology, University of Washington School of Medicine, Seattle, WA, USA; Department of Neurology, Peking University Third Hospital, Beijing, China.
出版信息
Alzheimers Dement. 2018 Aug;14(8):1052-1062. doi: 10.1016/j.jalz.2018.02.015. Epub 2018 Mar 28.
Abstract
INTRODUCTION
The ability of Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers (amyloid β peptide 1-42, total tau, and phosphorylated tau) to discriminate AD from related disorders is limited. Biomarkers for other concomitant pathologies (e.g., CSF α-synuclein [α-syn] for Lewy body pathology) may be needed to further improve the differential diagnosis.
METHODS
CSF total α-syn, phosphorylated α-syn at Ser129, and AD CSF biomarkers were evaluated with Luminex immunoassays in 367 participants, followed by validation in 74 different neuropathologically confirmed cases.
RESULTS
CSF total α-syn, when combined with amyloid β peptide 1-42 and either total tau or phosphorylated tau, improved the differential diagnosis of AD versus frontotemporal dementia, Lewy body disorders, or other neurological disorders. The diagnostic accuracy of the combined models attained clinical relevance (area under curve ∼0.9) and was largely validated in neuropathologically confirmed cases.
DISCUSSION
Combining CSF biomarkers representing AD and Lewy body pathologies may have clinical value in the differential diagnosis of AD.
摘要
简介
阿尔茨海默病（AD）脑脊液（CSF）生物标志物（β淀粉样蛋白 1-42、总 tau 和磷酸化 tau）区分 AD 与相关疾病的能力有限。可能需要其他伴随病理的生物标志物（例如，路易体病理的 CSF α-突触核蛋白 [α-syn]）来进一步改善鉴别诊断。
方法
采用 Luminex 免疫分析法检测 367 名参与者的 CSF 总 α-syn、磷酸化 α-syn 第 129 位丝氨酸和 AD CSF 生物标志物，随后在 74 例不同神经病理学确诊病例中进行验证。
结果
当 CSF 总 α-syn 与β淀粉样蛋白 1-42 以及总 tau 或磷酸化 tau 联合使用时，可以改善 AD 与额颞叶痴呆、路易体障碍或其他神经疾病的鉴别诊断。组合模型的诊断准确性达到了临床相关性（曲线下面积约为 0.9），并在神经病理学确诊病例中得到了广泛验证。
讨论
联合 AD 和路易体病理的 CSF 生物标志物可能在 AD 的鉴别诊断中具有临床价值。
相似文献
1
Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of Alzheimer's disease.脑脊液 α- 突触核蛋白有助于阿尔茨海默病的鉴别诊断。
Alzheimers Dement. 2018 Aug;14(8):1052-1062. doi: 10.1016/j.jalz.2018.02.015. Epub 2018 Mar 28.
2
Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.脑脊液脂肪酸结合蛋白 3、α-突触核蛋白与阿尔茨海默病核心生物标志物在路易体疾病和阿尔茨海默病痴呆中的差异作用。
Alzheimers Res Ther. 2017 Jul 28;9(1):52. doi: 10.1186/s13195-017-0276-4.
3
The value of cerebrospinal fluid α-synuclein and the tau/α-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology.脑脊液 α-突触核蛋白和 tau/α-突触核蛋白比值对具有路易体病理的神经退行性疾病的诊断价值。
Eur J Neurol. 2020 Jan;27(1):43-50. doi: 10.1111/ene.14032. Epub 2019 Jul 24.
4
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.帕金森病患者脑脊液中α-突触核蛋白和tau 浓度：一项队列研究。
Lancet Neurol. 2011 Mar;10(3):230-40. doi: 10.1016/S1474-4422(11)70014-X.
5
α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.α-突触核蛋白作为路易体痴呆症潜在的脑脊液生物标志物。
Mov Disord. 2018 Nov;33(11):1724-1733. doi: 10.1002/mds.111. Epub 2018 Nov 15.
6
Increased CSF α-synuclein levels in Alzheimer's disease: correlation with tau levels.阿尔茨海默病患者脑脊液中α-突触核蛋白水平升高：与tau 蛋白水平的相关性。
Alzheimers Dement. 2014 Oct;10(5 Suppl):S290-8. doi: 10.1016/j.jalz.2013.10.004. Epub 2014 Jan 15.
7
CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.阿尔茨海默病和路易体痴呆症中神经元损伤生物标志物视蛋白样蛋白-1 的 CSF 水平。
J Neurochem. 2013 Dec;127(5):681-90. doi: 10.1111/jnc.12331. Epub 2013 Jun 26.
8
CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease.脑脊液 α-突触核蛋白不能区分路易体痴呆与阿尔茨海默病。
J Alzheimers Dis. 2010;22(1):87-95. doi: 10.3233/JAD-2010-100186.
9
Measurement of CSF α-synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer's disease.脑脊液 α- 突触核蛋白测定有助于提高阿尔茨海默病所致轻度认知障碍的早期鉴别诊断。
J Neurochem. 2019 Jul;150(2):218-230. doi: 10.1111/jnc.14719. Epub 2019 Jul 8.
10
CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease.脑脊液 α-突触核蛋白提高了阿尔茨海默病中脑脊液 tau 和 Aβ 的诊断和预后性能。
Acta Neuropathol. 2013 Nov;126(5):683-97. doi: 10.1007/s00401-013-1148-z. Epub 2013 Jun 29.
引用本文的文献
1
Distinct CSF α-synuclein aggregation profiles associated with Alzheimer's disease phenotypes and MCI-to-AD conversion.与阿尔茨海默病表型及轻度认知障碍向阿尔茨海默病转化相关的不同脑脊液α-突触核蛋白聚集谱。
J Prev Alzheimers Dis. 2025 Feb;12(2):100040. doi: 10.1016/j.tjpad.2024.100040. Epub 2025 Jan 3.
2
Unlocking early detection of Alzheimer's disease: The emerging role of nanomaterial-based optical sensors.解锁阿尔茨海默病的早期检测：基于纳米材料的光学传感器的新兴作用。
J Food Drug Anal. 2024 Sep 13;32(3):296-324. doi: 10.38212/2224-6614.3520.
3
Potential Mechanisms of Tunneling Nanotube Formation and Their Role in Pathology Spread in Alzheimer's Disease and Other Proteinopathies.隧道纳米管形成的潜在机制及其在阿尔茨海默病和其他蛋白病中病理扩散中的作用。
Int J Mol Sci. 2024 Oct 8;25(19):10797. doi: 10.3390/ijms251910797.
4
Validity of CSF alpha-synuclein to predict psychosis in prodromal Alzheimer's disease.脑脊液α-突触核蛋白预测前驱期阿尔茨海默病患者发生精神病的效度
Front Neurol. 2023 May 24;14:1124145. doi: 10.3389/fneur.2023.1124145. eCollection 2023.
5
CSF biomarkers for early-onset Alzheimer's disease in Chinese population from PUMCH dementia cohort.北京协和医院痴呆队列中中国人群早发型阿尔茨海默病的脑脊液生物标志物
Front Neurol. 2023 Jan 9;13:1030019. doi: 10.3389/fneur.2022.1030019. eCollection 2022.
6
Alpha-synuclein: a pathological factor with Aβ and tau and biomarker in Alzheimer's disease.α-突触核蛋白：阿尔茨海默病中的 Aβ 和 tau 病理因素及生物标志物。
Alzheimers Res Ther. 2022 Dec 31;14(1):201. doi: 10.1186/s13195-022-01150-0.
7
Asthma amplifies dementia risk: Evidence from CSF biomarkers and cognitive decline.哮喘增加痴呆风险：来自脑脊液生物标志物和认知衰退的证据。
Alzheimers Dement (N Y). 2022 Jul 8;8(1):e12315. doi: 10.1002/trc2.12315. eCollection 2022.
8
Relation between Alpha-Synuclein and Core CSF Biomarkers of Alzheimer's Disease.α-突触核蛋白与阿尔茨海默病核心 CSF 生物标志物的关系。
Medicina (Kaunas). 2021 Sep 10;57(9):954. doi: 10.3390/medicina57090954.
9
The Association Between Plasma α-Synuclein (α-syn) Protein, Urinary Alzheimer-Associated Neuronal Thread Protein (AD7c-NTP), and Apolipoprotein Epsilon 4 (ApoE ε4) Alleles and Cognitive Decline in 60 Patients with Alzheimer's Disease Compared with 28 Age-Matched Normal Individuals.血浆α-突触核蛋白（α-syn）、尿阿尔茨海默病相关神经丝蛋白（AD7c-NTP）与载脂蛋白 E ɛ4（ApoE ε4）等位基因与 60 例阿尔茨海默病患者认知下降的关系，并与 28 例年龄匹配的正常个体进行比较。
Med Sci Monit. 2021 Jul 27;27:e932998. doi: 10.12659/MSM.932998.
10
Development of a Sensitive Diagnostic Assay for Parkinson Disease Quantifying α-Synuclein-Containing Extracellular Vesicles.开发一种用于帕金森病诊断的灵敏检测方法，定量检测含有α-突触核蛋白的细胞外囊泡。
Neurology. 2021 May 4;96(18):e2332-e2345. doi: 10.1212/WNL.0000000000011853. Epub 2021 Mar 23.
本文引用的文献
1
Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia.在无痴呆的帕金森病中，局部脑区淀粉样β蛋白积聚与特定领域的认知表现相关。
PLoS One. 2017 May 25;12(5):e0177924. doi: 10.1371/journal.pone.0177924. eCollection 2017.
2
Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.在结构化的五阶段研发框架背景下，脑脊液β淀粉样蛋白42（Aβ42）、tau蛋白和磷酸化tau蛋白作为阿尔茨海默病生物标志物的临床有效性
Neurobiol Aging. 2017 Apr;52:196-213. doi: 10.1016/j.neurobiolaging.2016.02.034.
3
Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer's disease.在被诊断为可能患有阿尔茨海默病的患者中，脑脊液总水平升高，但寡聚体或磷酸化形式的α-突触核蛋白没有升高。
Sci Rep. 2017 Jan 10;7:40263. doi: 10.1038/srep40263.
4
Multiparametric computer-aided differential diagnosis of Alzheimer's disease and frontotemporal dementia using structural and advanced MRI.使用结构和高级磁共振成像对阿尔茨海默病和额颞叶痴呆进行多参数计算机辅助鉴别诊断。
Eur Radiol. 2017 Aug;27(8):3372-3382. doi: 10.1007/s00330-016-4691-x. Epub 2016 Dec 16.
5
Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis.突触核蛋白病生存及痴呆症发病的神经病理学和遗传学关联：一项回顾性分析
Lancet Neurol. 2017 Jan;16(1):55-65. doi: 10.1016/S1474-4422(16)30291-5.
6
CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease.在帕金森病中，通过外泌体的中枢神经系统tau蛋白外流可能增加，但在阿尔茨海默病中并非如此。
Alzheimers Dement. 2016 Nov;12(11):1125-1131. doi: 10.1016/j.jalz.2016.04.003. Epub 2016 May 24.
7
Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease.寡聚化和磷酸化的α-突触核蛋白作为帕金森病潜在的脑脊液生物标志物
Mol Neurodegener. 2016 Jan 19;11:7. doi: 10.1186/s13024-016-0072-9.
8
Alzheimer Disease and Behavioral Variant Frontotemporal Dementia: Automatic Classification Based on Cortical Atrophy for Single-Subject Diagnosis.阿尔茨海默病和行为变异额颞叶痴呆：基于皮质萎缩的单病例诊断自动分类。
Radiology. 2016 Jun;279(3):838-48. doi: 10.1148/radiol.2015150220. Epub 2015 Dec 11.
9
The past and the future of Alzheimer's disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular events.阿尔茨海默病脑脊液生物标志物的过去与未来——迈向涵盖分子事件全谱的经过验证的生化检测之旅。
Front Neurosci. 2015 Sep 29;9:345. doi: 10.3389/fnins.2015.00345. eCollection 2015.
10
Increased CSF E-Selectin in Clinical Alzheimer's Disease without Altered CSF Aβ42 and Tau.临床阿尔茨海默病患者脑脊液中E-选择素增加，而脑脊液中Aβ42和Tau未改变。
J Alzheimers Dis. 2015;47(4):883-7. doi: 10.3233/JAD-150420.
Zotero 插件